Suppr超能文献

奥美拉唑和雷尼替丁对犬和大鼠胃酸分泌、血液胃泌素水平及胃黏膜[3H]-胸腺嘧啶核苷掺入的影响。

Effects of omeprazole and ranitidine on gastric acid secretion, blood gastrin levels and [3H]-thymidine incorporation in the oxyntic mucosa from dogs and rats.

作者信息

Ryberg B, Mattsson H, Carlsson E

机构信息

Department of Biology, AB Hässle, Mölndal, Sweden.

出版信息

Digestion. 1988;39(2):91-9. doi: 10.1159/000199611.

Abstract

Dogs provided with a gastric fistula were treated orally for 1 week either with the H+, K+-ATPase inhibitor omeprazole, 80 mumol/kg once daily, or with the histamine H2 receptor antagonist ranitidine, 85-175 mumol/kg every 8 h. Acid secretion, serum gastrin levels and [3H]-thymidine incorporation in the corpus mucosa were determined before, during and after the treatment period. In order to examine differences between species, plasma gastrin levels and [3H]-thymidine incorporation in the oxyntic mucosa were also determined in female rats treated up to 1 week with omeprazole, 400 mumol/kg orally once daily. Histamine-stimulated gastric acid secretion in dogs treated with omeprazole or ranitidine was almost completely inhibited during the whole treatment period. As a consequence of that, the meal-stimulated gastrin levels were increased (7-fold) during treatment by both compounds. [3H]-thymidine incorporation in the dog corpus mucosa was increased approximately 4 times on day 5 both with omeprazole and ranitidine. After the treatment was stopped, gastric acid secretion, serum levels of gastrin and the rate of [3H]-thymidine incorporation were back to control level in both groups within 11 days. In the rats, the plasma gastrin levels increased 10-fold and the rate of [3H]-thymidine incorporation in the corpus mucosa increased 3-fold during treatment with omeprazole. In conclusion, a pronounced suppression of gastric acid secretion over the day with antisecretagogues results in hypergastrinemia in both dogs and rats. As a consequence of the trophic effect of gastrin, the incorporation of [3H]-thymidine in the oxyntic mucosa is increased.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

给具有胃瘘的狗口服治疗1周,分别给予H⁺,K⁺ - ATP酶抑制剂奥美拉唑(80 μmol/kg,每日1次)或组胺H₂受体拮抗剂雷尼替丁(85 - 175 μmol/kg,每8小时1次)。在治疗期之前、期间和之后测定胃酸分泌、血清胃泌素水平以及胃体黏膜中[³H] - 胸腺嘧啶核苷掺入情况。为了研究种属间差异,还对每日口服给予奥美拉唑(400 μmol/kg)达1周的雌性大鼠测定了血浆胃泌素水平以及胃底黏膜中[³H] - 胸腺嘧啶核苷掺入情况。在整个治疗期,用奥美拉唑或雷尼替丁治疗的狗,组胺刺激的胃酸分泌几乎完全受到抑制。因此,两种化合物治疗期间餐刺激的胃泌素水平均升高(7倍)。奥美拉唑和雷尼替丁治疗第5天时,狗胃体黏膜中[³H] - 胸腺嘧啶核苷掺入量均增加约4倍。停止治疗后,两组的胃酸分泌、血清胃泌素水平以及[³H] - 胸腺嘧啶核苷掺入率在11天内均恢复至对照水平。在大鼠中,用奥美拉唑治疗期间血浆胃泌素水平升高10倍,胃体黏膜中[³H] - 胸腺嘧啶核苷掺入率升高3倍。总之,一天中用抑分泌剂显著抑制胃酸分泌会导致狗和大鼠出现高胃泌素血症。由于胃泌素的营养作用,胃底黏膜中[³H] - 胸腺嘧啶核苷的掺入增加。(摘要截短至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验